BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.5%

Neg 0% Neu 90.5% Pos 0%

BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.

Comments

No comments yet. Be the first!